The general public will subscribe 6.25 million shares, 25 percent of the total offer size of BF Biosciences IPO on October 2nd and 3rd at the strike price of Rs. 77.

The general public can subscribe to the IPO on 2nd and 3rd October from 9.00 am to 5 pm during banking hours. However, in the case of e-IPO, the process continues for 24 hours.

The book-building phase of BF Biosciences concluded last week with an oversubscription of 3.4 times.
The IPO received an overwhelming response from institutional investors and high-net-worth individuals as the strike price clocked in at Rs. 77/share, 40 percent higher than the floor price of Rs. 55 and raised Rs. 1.93 billion.

Shahid Ali, CEO Arif Habib Limited said that investing in the public offering of BF Biosciences presents a decent opportunity for retail investors to engage with a fundamentally strong company at a more attractive valuation compared to the broader pharmaceutical sector.

This unique positioning allows investors to capitalize on potential growth while benefiting from a favorable entry point.